Zoetis Inc. $ZTS Shares Purchased by iA Global Asset Management Inc.

iA Global Asset Management Inc. boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 38.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,480 shares of the company’s stock after purchasing an additional 9,628 shares during the quarter. iA Global Asset Management Inc.’s holdings in Zoetis were worth $5,045,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC increased its stake in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the last quarter. REAP Financial Group LLC boosted its stake in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the last quarter. NewSquare Capital LLC grew its holdings in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. ORG Partners LLC raised its stake in shares of Zoetis by 56.8% in the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after purchasing an additional 84 shares in the last quarter. Finally, Financial Consulate Inc. acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $39,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $124.04 on Friday. The firm has a fifty day moving average of $123.58 and a 200-day moving average of $138.43. The company has a market cap of $54.66 billion, a price-to-earnings ratio of 20.88, a price-to-earnings-growth ratio of 2.16 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. During the same period last year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s dividend payout ratio is presently 35.69%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday. Stifel Nicolaus lowered their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Five analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.